Ivana Ritter

646 total citations · 1 hit paper
11 papers, 241 citations indexed

About

Ivana Ritter is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, Ivana Ritter has authored 11 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Nephrology. Recurrent topics in Ivana Ritter's work include Diabetes Treatment and Management (7 papers), Chronic Kidney Disease and Diabetes (4 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Ivana Ritter is often cited by papers focused on Diabetes Treatment and Management (7 papers), Chronic Kidney Disease and Diabetes (4 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Ivana Ritter collaborates with scholars based in United Kingdom, Germany and United States. Ivana Ritter's co-authors include Bettina J. Kraus, Christoph Wanner, Silvio E. Inzucchi, Matthew R. Weir, Maximilian von Eynatten, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Hiddo J.L. Heerspink and George L. Bakris and has published in prestigious journals such as New England Journal of Medicine, Diabetes Care and Kidney International.

In The Last Decade

Ivana Ritter

7 papers receiving 236 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nerandomilast in Patients with Progressive Pulmonary Fibrosis

2025 19 citations Toby M. Maher, Shervin Assassi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivana Ritter United Kingdom	4	184	93	62	54	49	11	241
Atit Dharia Canada	6	170 0.9×	46 0.5×	39 0.6×	78 1.4×	63 1.3×	11	272
Krishmita Siwakoti United States	5	212 1.2×	97 1.0×	121 2.0×	105 1.9×	29 0.6×	13	318
Stephen Gough Denmark	6	184 1.0×	76 0.8×	42 0.7×	167 3.1×	30 0.6×	12	322
Mie K. Eickhoff Denmark	6	106 0.6×	32 0.3×	35 0.6×	89 1.6×	52 1.1×	12	223
Nisha Suda United States	2	201 1.1×	90 1.0×	119 1.9×	99 1.8×	29 0.6×	5	275
Donna Shu‐Han Lin Taiwan	9	200 1.1×	55 0.6×	83 1.3×	83 1.5×	25 0.5×	26	302
Hans-Ulrich Haering Germany	8	94 0.5×	29 0.3×	84 1.4×	75 1.4×	21 0.4×	19	247
Zi Michael Miao United Kingdom	12	172 0.9×	59 0.6×	255 4.1×	50 0.9×	14 0.3×	21	341
Mikhail Kosiborod United States	6	229 1.2×	48 0.5×	183 3.0×	97 1.8×	11 0.2×	13	334
E. Andrikou Greece	10	99 0.5×	32 0.3×	134 2.2×	45 0.8×	39 0.8×	24	276

Countries citing papers authored by Ivana Ritter

Since Specialization

Citations

This map shows the geographic impact of Ivana Ritter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivana Ritter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivana Ritter more than expected).

Fields of papers citing papers by Ivana Ritter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivana Ritter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivana Ritter. The network helps show where Ivana Ritter may publish in the future.

Co-authorship network of co-authors of Ivana Ritter

This figure shows the co-authorship network connecting the top 25 collaborators of Ivana Ritter. A scholar is included among the top collaborators of Ivana Ritter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivana Ritter. Ivana Ritter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2203–2214. 19 indexed citations breakdown →

2.

Ritter, Ivana, et al.. (2025). Isavuconazole in chronic pulmonary aspergillosis: What is the evidence?. Journal of Infection and Chemotherapy. 31(6). 102704–102704.

3.

Cottin, Vincent, Claudia Valenzuela, Heng Gu, et al.. (2025). LB0003 EFFICACY AND SAFETY OF NERANDOMILAST IN PATIENTS WITH AUTOIMMUNE DISEASE–RELATED PROGRESSIVE PULMONARY FIBROSIS: SUBGROUP ANALYSIS OF THE FIBRONEER-ILD TRIAL. Annals of the Rheumatic Diseases. 84. 315–316.

4.

Chaudhuri, Nazia, et al.. (2024). Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data. Advances in Therapy. 41(12). 4581–4590. 2 indexed citations

5.

Tuttle, Katherine R., Adeera Levin, Masaomi Nangaku, et al.. (2022). Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 45(6). 1445–1452. 30 indexed citations

6.

Ferreira, João Pedro, Faı̈ez Zannad, Javed Butler, et al.. (2022). Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal. 43(31). 2984–2993. 51 indexed citations

7.

Agarwal, Rajiv, Sibylle J. Hauske, David C. Wheeler, et al.. (2022). Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals. Diabetes Obesity and Metabolism. 24(7). 1390–1393.

8.

Tuttle, Katherine R., Adeera Levin, Masaomi Nangaku, et al.. (2022). Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Figshare. 2 indexed citations

9.

Mattheus, Michaela, Naveed Sattar, Ivana Ritter, et al.. (2021). Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie und Stoffwechsel. 16.

10.

Kraus, Bettina J., Matthew R. Weir, George L. Bakris, et al.. (2020). Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International. 99(3). 750–762. 136 indexed citations

11.

Kraus, Bettina J., Matthew R. Weir, George L. Bakris, et al.. (2020). LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact